Pfizer head to be ABPI president
pharmafile | December 4, 2013 | News story | Medical Communications, Sales and Marketing | ABPI, MSD, PPRS, Pfizer, Whitehead, emms, khanna
The UK managing director of Pfizer Jonathan Emms is to replace Deepak Khanna as the ABPI president from April next year.
Like the ABPI, Emms has been highly critical of the government’s upcoming drug pricing scheme, and often highlights the increasing – but disputed – costs of drug development.
Taking over from Khanna, who is also the head of MSD UK, Emms will serve for one year with the option of standing for re-election for a further year.
Emms started his career at GSK before joining Pfizer in 1999. In January last year he took up the role of UK managing director. Prior to this he held a number of roles across the firm, including spending six years in France establishing European regional teams as as marketing head.
Khanna will continue to lead the organisation prior to Emms taking over the presidency in April, and will be working on embedding the new aforementioned voluntary pricing scheme, which begins on 1 January.
Emms who is a board member at the ABPI, said: “I am immensely proud to work in an industry which makes such a positive difference to the health of millions of people both in the UK and around the world. It is an honour to be elected as president of the ABPI from April 2014 and to lead our industry at such a crucial time.”
Stephen Whitehead, ABPI chief executive added: “I am very much looking forward to working with Jonathan when he starts his presidency in April 2014. This is a significant time for a new president as we enter a new pricing era, and I have no doubt that Jonathan will provide strong leadership to the ABPI and the industry as a whole.”
Brett Wells
Related Content
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …
Pfizer releases results for severe RSV-associated LRTD treatment study
US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical …
Merck and Daiichi Sankyo expand development and commericalisation agreement to include MK-6070
Daiichi Sankyo and Merck (known as MSD outside of the US and Canada) have announced …
